By Sabela Ojea

AstraZeneca PLC said Friday that the Propel Phase 3 trial met its primary point, proving that its Lynparza drug significantly delayed disease progression of first-line metastatic castration-resistant prostate cancer in combination with the abiraterone drug.

The biopharmaceutical company said the results from the trial showed positive results, including a trend towards improved overall survival.

The London-listed company noted that prostate cancer is the second most common cancer.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

September 24, 2021 02:31 ET (06:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.